Aberrant STAT3 activation in HCC is mainly mediated by interleukin-6 (IL-6) trans-signaling and is, therefore, commonly referred to as IL-6/STAT3 axis alteration [309,310,311]. The gene discussed is IL6; the disease is hepatocellular carcinoma.